These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31517531)

  • 1. The search for improved animal models of Alzheimer's disease and novel strategies for therapeutic intervention.
    Li C; Briner A; Götz J
    Future Med Chem; 2019 Aug; 11(15):1853-1857. PubMed ID: 31517531
    [No Abstract]   [Full Text] [Related]  

  • 2. Application of yeast to study the tau and amyloid-β abnormalities of Alzheimer's disease.
    Porzoor A; Macreadie IG
    J Alzheimers Dis; 2013; 35(2):217-25. PubMed ID: 23396350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal death in Alzheimer's disease.
    Yanagisawa K
    Intern Med; 2000 Apr; 39(4):328-30. PubMed ID: 10801151
    [No Abstract]   [Full Text] [Related]  

  • 4. [Development of animal models for therapy of Alzheimer's disease].
    Shoji M
    Nihon Ronen Igakkai Zasshi; 2003 Jan; 40(1):27-9. PubMed ID: 12649842
    [No Abstract]   [Full Text] [Related]  

  • 5. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
    Götz J; Schild A; Hoerndli F; Pennanen L
    Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late running is not too late against Alzheimer's pathology.
    Herring A; Münster Y; Metzdorf J; Bolczek B; Krüssel S; Krieter D; Yavuz I; Karim F; Roggendorf C; Stang A; Wang Y; Hermann DM; Teuber-Hanselmann S; Keyvani K
    Neurobiol Dis; 2016 Oct; 94():44-54. PubMed ID: 27312772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.
    Roberson ED; Scearce-Levie K; Palop JJ; Yan F; Cheng IH; Wu T; Gerstein H; Yu GQ; Mucke L
    Science; 2007 May; 316(5825):750-4. PubMed ID: 17478722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
    Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
    Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration.
    Kuo YC; Chen CL; Rajesh R
    Acta Biomater; 2019 Mar; 87():207-222. PubMed ID: 30716553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The search for better animal models of Alzheimer's disease.
    King A
    Nature; 2018 Jul; 559(7715):S13-S15. PubMed ID: 30046083
    [No Abstract]   [Full Text] [Related]  

  • 12. [Transmission of pathogenic protein aggregates in Alzheimer's disease].
    Schwarzman AL; Sarantseva SV
    Mol Biol (Mosk); 2017; 51(3):418-422. PubMed ID: 28707657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What's next for Alzheimer treatment?: while Aβ isn't out of the picture yet, several other therapeutic routes are being explored.
    Schwartz A
    Ann Neurol; 2013 Apr; 73(4):A7-9. PubMed ID: 24643982
    [No Abstract]   [Full Text] [Related]  

  • 14. Testing the Amyloid Hypothesis with a Humanized AD Mouse Model.
    Cahill MK; Huang EJ
    Neuron; 2017 Mar; 93(5):987-989. PubMed ID: 28279360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau therapeutics for Alzheimer's disease: the promise and the challenges.
    Gold M
    J Mol Neurosci; 2002 Dec; 19(3):331-4. PubMed ID: 12540060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidating the triggers, progression, and effects of Alzheimer's disease.
    Medeiros R; Chabrier MA; LaFerla FM
    J Alzheimers Dis; 2013; 33 Suppl 1():S195-210. PubMed ID: 22635105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics.
    Sala Frigerio C; De Strooper B
    Annu Rev Neurosci; 2016 Jul; 39():57-79. PubMed ID: 27050320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
    Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
    Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanical stress models of Alzheimer's disease pathology.
    Levy Nogueira M; Epelbaum S; Steyaert JM; Dubois B; Schwartz L
    Alzheimers Dement; 2016 Mar; 12(3):324-33. PubMed ID: 26718585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yeast Model of Amyloid-β and Tau Aggregation in Alzheimer's Disease.
    Moosavi B; Mousavi B; Macreadie IG
    J Alzheimers Dis; 2015; 47(1):9-16. PubMed ID: 26402750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.